‹ ›
MYP_025572
← PREVIOUS NEXT → BACK
Basic Information
Abarelix
Anticancer
Hormonal / Endocrine ▸ Hormone peptide
not Standard
10 amino acids
-
contains X representing unresolved or non-standard residue
Sequence
XXXSXNLXPA
Physicochemical Analysis
0.00 Da
0.00
0.00
0.00
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0045722 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]; synthetic construct [Synthetic]
GnRH
9606;32630
Structure & Mods
linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Acetylation
Amidation
Non-standard residues/X at 1, 2, 3, 5, 8
Bio-Activity Profile
GnRH antagonist Endocrine Anticancer
Healthy male subjects; luteinizing hormone suppression
0.00425 μg/mL
IC50
Clinical/Human: 0.22 d (5.3 h) for abarelix injectable solution and 13.2 d for abarelix depot injection
PaperPharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone antagonist PMID15102870 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15102870/
RECORD: Rec_0128704 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]; synthetic construct [Synthetic]
GnRH
9606;32630
Structure & Mods
linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Acetylation
Amidation
Non-standard residues/X at 1, 2, 3, 5, 8
Bio-Activity Profile
GnRH antagonist Endocrine Anticancer
Healthy male subjects; dihydrotestosterone suppression
0.00342 μg/mL
IC50
Clinical/Human: 0.22 d (5.3 h) for abarelix injectable solution and 13.2 d for abarelix depot injection
PaperPharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone antagonist PMID15102870 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15102870/
RECORD: Rec_0177608 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]; synthetic construct [Synthetic]
GnRH
9606;32630
Structure & Mods
linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Acetylation
Amidation
Non-standard residues/X at 1, 2, 3, 5, 8
Bio-Activity Profile
GnRH antagonist Endocrine Anticancer
Healthy male subjects; testosterone suppression
0.00208 μg/mL
IC50
Clinical/Human: 0.22 d (5.3 h) for abarelix injectable solution and 13.2 d for abarelix depot injection
PaperPharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone antagonist PMID15102870 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15102870/
RECORD: Rec_0384826 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]; synthetic construct [Synthetic]
GnRH
9606;32630
Structure & Mods
linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Acetylation
Amidation
Non-standard residues/X at 1, 2, 3, 5, 8
Bio-Activity Profile
GnRH antagonist Endocrine Anticancer
Healthy male subjects; follicle-stimulating hormone suppression
0.00643 μg/mL
IC50
Clinical/Human: 0.22 d (5.3 h) for abarelix injectable solution and 13.2 d for abarelix depot injection
PaperPharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone antagonist PMID15102870 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15102870/